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Abstract Drug-discovery has become a complex disci-
pline in which the amount of knowledge about human
biology, physiology, and biochemistry have increased. In
order to harness this complex body of knowledge mathe-
matics can play a critical role, and has actually already
been doing so. We demonstrate through four case studies,
taken from previously published data and analyses, what
we can gain from mathematical/analytical techniques when
nonlinear concentration-time courses have to be trans-
formed into their equilibrium concentration-response (tar-
get or complex) relationships and new structures of drug
potency have to be deciphered; when pattern recognition
needs to be carried out for an unconventional response-
time dataset; when what-if? predictions beyond the obser-
vational concentration-time range need to be made; or
when the behaviour of a semi-mechanistic model needs to
be elucidated or challenged. These four examples are
typical situations when standard approaches known to the
general community of pharmacokineticists prove to be
inadequate.
Keywords Receptors  Drug-disposition  Dose-response-
time analysis  Michaelis-menten  Quasi-steady-state 
Singular perturbations
Introduction
In recent years application of mathematics in drug devel-
opment has gained momentum. Even the FDA is consid-
ering approval of compounds in part on the basis of
arguments based on modelling and simulation (cf. [1]). But
there is a great variety of ways in which mathematics can
play a role in drug discovery and development. On the one
hand, the industrial scientist is often faced with the prob-
lem to make reliable predictions about such issues as
optimal dose or assessment of safety, on the basis of data
about onset, intensity and duration of response, when
quantitative information about the underlying mechanism
of action is limited. The challenge is then to combine
available physiological knowledge, well-designed experi-
ments and mathematical analysis to develop a model which
can be used to make such reliable predictions. In addition,
with expanding knowledge about biological and physio-
logical processes, more systems-based studies are being
carried out in which mathematical ideas about dynamical
systems are used, for instance, to model complex regula-
tory networks, or gain insight in the behaviour of such
networks, i.e. locate sensitive spots (cf. [2, 3]).
We demonstrate the role mathematics can play in vari-
ous aspects of pharmacology, such as (i) analysing com-
plex data sets; (ii) using mathematical reasoning for
dissecting model structure and acquiring quantitive infor-
mation out of unconventional response-time courses; (iii)
predicting the effect of chronic drug exposure on the basis
of relatively short-time data sets in the context of disease
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progression. Finally, (iv) we show how mathematical
analysis can help to discover when a model is not Well-
Posed1 [4]. and statistical analysis yields unexpected and
counter-intuitive results. We discuss these examples of
mathematics in four case studies:
1. Probing the complexity of Target-Mediated Drug
Disposition.
2. Using Visual Inspection to estimate model parame-
ters—pattern recognition.
3. Model predictions beyond the experimental range.
4. Vetting a model that yields counter-intuitive concen-
tration-versus-time graphs.
The analyses presented in these four cases are based on
results published in, respectively [5–8].
Probing the complexity of target-mediated drug
disposition
Large molecule compounds, such as monoclonal antibod-
ies, exhibit interesting nontrivial interactions with their
target, involving binding, saturation and target turnover.
This results in complex ligand-concentration versus time
courses. In Fig. 1 we show a typical such data set.
Their dynamics is often referred to as Target-Mediated
Drug Disposition and has been the subject of many studies
(e.g. Mager et al [9–11], Gibiansky et al [12], Krippendorff
et al [13], Peletier et al [14, 15], Ma [16] and Dua et al
[17]). Characteristically, the concentration-time courses
display a series of phases. Initially they exhibit a quick
drop, which may easily be missed if the first plasma sample
is 12–24 h post dose. Then the curves display a concave
bend towards a slower decline. Here, at higher exposure of
ligand, one often has first-order linear (dose-proportional)
kinetics.
The third typical phase is a convex bend downward with
a shorter apparent half-life as we approach lower concen-
trations. This is where elimination of ligand through target
internalisation starts to contribute. The kinetics is now
nonlinear. Interestingly, the downward bend occurs at a
ligand concentration which is independent of the dose.
Throughout this phase the target route of elimination is
more or less saturable, but less and less so as concentra-
tions decrease.
Finally, the ligand concentration enters a slower termi-
nal phase, again after a concave bend, with a longer
apparent half-life.
The model
The disposition of the antibody (ligand, L) is described by a
two-compartment disposition model, involving a plasma-
and a tissue compartment, coupled to a target pool (R) with
zero-order production and first-order loss. Ligand and tar-
get form a target-ligand complex RL via a second-order
process. The complex can either be degraded into ligand
and target via the first-order koff process or be irreversibly
lost via keðRLÞ (first-order internalisation). (Fig. 2)
The combination of the second order formation and first-
order loss of complex results in the following nonlinear
system involving the concentrations of ligand in the central
compartment (L) and in the tissue compartment (Lt), and of
target (R) and ligand-target complex (RL):
dL
dt






¼ ksyn  kdegR konL  Rþ koffRL
dRL
dt



























in which Input denotes the zeroth order input flux, ClL the
first-order non-specific clearance, Cld the inter-
Fig. 1 Semi-logarithmic plot of observed (symbols) and TMDD
model predicted ligand concentrations in the central compartment
(solid lines) at four different doses of 1.5, 5, 15 and 45 mg/kg after
rapid intravenous injections of a monoclonal antibody. Note that the
ligand concentration displays a multi-step pattern that changes in
shape as the ligand exposure (dose) decreases. The plot also shows the
target baseline concentration in plasma R0, the estimated dissociation
constant Kd and the associated Michaelis-Menten constant Km (cf.
Peletier and Gabrielsson [15])
1 A problem is well posed if: (i) it has a solution, (ii) the solution is
unique, (iii) the solution depends smoothly on parameters and initial
data
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compartmental distribution, and Vc and Vt the volume of
the central- and the tissue compartment.
Steady states
In Fig. 3 we show how the steady-state concentrations of
ligand, target and ligand-target complex vary as the infu-
sion rate kinfus changes when the parameter values are given
by Table 1. Note that at steady state the ligand concen-
trations in the central and the peripheral compartment are
the same.
For the values of Table 1, the dissociation constant is
Kd ¼ koff=kon ¼ 0:011 mg/L and the Michaelis-Menten
constant Km ¼ ðkoff þ keðRLÞÞ=kon ¼ 0:044 mg/L.
The graphs in Fig. 3 are complex and offer unique
diagnostic material to asses the strength of the different
processes and the values of the parameters under very
general conditions. Besides, whether or not there is a tissue
compartment makes no difference, the steady states are the
same.
The curves for Lss, Rss and RLss, have nontrivial shapes.
For instance, in the figure on the left in which they are
plotted linearly, they have the following properties:
(i) They each consist of two segments that are
approximately linear.
(ii) The two approximately linear segments are joined
at a narrow interface located at approximately
kinfus ¼ ksyn ¼ 0:11 (mg/L)/h.
Mathematical analysis
The slopes of these segments are well-defined and can be
computed explicitly. Hence, their dependence on the
parameters of the system (1) is transparent. Specifically, for
the ligand-receptor complex RL one can prove for the slope
(A) at low infusion rates:









At a critical value, when kinfus  ksyn, the growth of RL
stops abruptly and the graph becomes flat. The level (R) at
which this happens is given by:
RLss ! R ¼
def ksyn
keðRLÞ
as kinfus ! 1 ð4Þ
Thus, the complex increases more or less linearly up to a
plateau where it abruptly levels off. The height of this
plateau depends on two parameters only: the synthesis rate
of receptor ksyn and the elimination rate keðRLÞ of ligand-
receptor complex.
Similarly, for the ligand Lss versus kinfus curve we find




 A  kinfus as kinfus ! 0 ð5Þ
For the data of Table 1, Km  R0 so that the initial slope of
Lss is much smaller than that of RLss. This is also evident in
Fig. 3.





ðkinfus  ksynÞ as kinfus ! 1 ð6Þ
This shows that Lss climbs as kinfus increases more or less
along a straight line with slope 1=keðLÞ and shifted to the
right by an amount equal to ksyn.
Because Lss depends monotonically on the infusion rate,
one can also express the steady state values of RL and R in




















According to (7) the graphs of Rss and RLss have a familiar
sigmoidal shape with different limits at large and small
ligand concentrations. They are shown in Fig. 4:
In particular, the limits at small and large ligand con-
centrations are given by
Fig. 2 Schematic description of target-mediated drug disposition.
Ligand L is distributed over a central- and a tissue compartment with
respective volumes Vc and Vt , is eliminated again via a first order
process (keðLÞ ¼ ClðLÞ=VcÞ, and binds reversibly (kon=koff ) to the target
R to form a ligand-target complex RL, which then is irreversibly
removed via a first order rate process (keðRLÞ)
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Rss ! R0 and RLss ! 0 as Lss ! 0
Rss ! 0 and RLss ! R as Lss ! 1
ð9Þ
and for both curves the ligand values for which they reach











Detailed information about the asymptotic formulae (3)–
(6) and the expressions (7) and (8) can be obtained from
explicit analytical expressions for the way the





























Fig. 3 The steady-state
concentrations Lss, Rss and RLss
graphed versus the infusion rate
kinfus, on a linear scale (left) and
on a log-log scale (right) for
parameter values taken from
Table 1
Table 1 Parameter values
taken from Peletier et al, [15]
Parameter Value Unit Description
keðLÞ 0.0015 h1 Ligand elimination rate
kon 0.091 {(mg/L)h}1 Binding rate
koff 0.001 h1 Dissociation rate
ksyn 0.11 (mg/L)/h Target synthesis rate
kdeg 0.0089 h1 Target degeneration rate
keðRLÞ 0.003 h1 Complex elimination rate
R0 12 mg/L Target baseline
R 37 mg/L Target maximum
Vc 0.05 L/kg Volume central compartment
Vt 0.1 L/kg Volume tissue compartment
Fig. 4 Target suppression Rss and complex formation RLss at equilibrium versus the steady state ligand concentration Lss. The fractional target-
turnover rate kdeg is faster (left), slower (middle) and equal (right) than the complex turnover rate keðRLÞ
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concentrations depend on the infusion rate kinfus. They are
given in Gabrielsson and Peletier [5].
Conclusion
We have seen how the complexity of the TMDD model is
elegantly depicted by plotting the steady states of the
compounds L, R and RL versus the infusion rate kinfus (cf.
Fig. 3). The graphs can be computed explicitly and depend
critically on the initial amount of target R0 and what one
could call a generalised dissociation constant which






If Km  R0, a common situation (cf [10, 15, 18]), the
graphs are almost piece-wise linear and the explicit
expressions for the slopes are quite simple.
Dependence of target-ligand complex formation RL and
receptor suppression R on the ligand concentration, proves
to be described by graphs of simple sigmoidal functions
(cf. Fig. 4). This introduces a potency parameter L50 which
is related to Km by the quotient of the two target elimina-





Thus, a close analysis of the steady state properties of the
three compounds involved in target-mediated disposition
reveals a great deal about the relative importance of the
sub-processes involved, and offers the possibility to
acquire quantitative information about them.
Using visual inspection to estimate model
parameters
This case study is aimed at demonstrating how mathe-
matical reasoning can be used to help the modeller in
choosing appropriate models on the basis of pharmacoki-
netic and pharmacodynamics data sets. This becomes
especially important when little is known about the
underlying pharmacokinetics, e.g., when the drug is not
supplied to the plasma. Thus, for such situations the only
data available are for response over time for different doses
and forms of administration. Study of such problems is
often referred to as dose-response-time analysis. It goes
back to early papers by Levy [19] and [20] and Smolen
[21]. For further references we refer to [6, 22–28]. Specific
questions such as (i) How does mathematical reasoning
address what is observed in onset, intensity and duration of
response, and (ii) How to choose an appropriate model are
discussed.
Data, model and equations
The data set records the locomotor activity, measured by
the number of times moving rats interrupted three light
beams in a cage when they were supplied by a drug,
(dexamphetamine). In the absence of dexamphetamine the
number of interruptions was negligible, but it goes up when
the drug is given. The exact mode of action of drug is not
known, and therefore an empirical mathematical model is
proposed.
Data shown in Fig. 5 were obtained and digitized from
Van Rossum and Van Koppen [29]. They recorded the
locomotor activity score after administration of dexam-
phetamine to rats at two dose levels (3.12 and 5.62 lg
kg-1). The data set was unusual because (i) the rise and
drop of response were approximately linear with time and
(ii) the slope of the increase and of the decline in the
locomotor activity score was independent of dose. In
addition, the transition from increase to decline was rela-
tively rapid.
Because the exposure to testcompound (drug) was not
known, a classic biophase model was fitted, one in which
the drug is administered through an intravenous bolus
administration. The amount of drug Ab in the biophase (in
lg) is described by the equation:
AbðtÞ ¼ F  D  ek t ð13Þ
where D denotes the dose (in lg), and F the biophase
availability, i.e., the fraction of the dose that reaches the
biophase, and k the elimination rate of the drug out of the
biophase.
Fig. 5 Locomotor activity scores (number of interruptions per
minute)-versus-time data following two subcutaneous 3.12 and 5.62
lg kg-1 doses of dexamphetamine (Van Rossum and Van Koppen
[29]). The solid lines represent predictions from fitting the model (14)
to the experimental data. Note the apparently linear and parallel
decline in response over time independently of dose
J Pharmacokinet Pharmacodyn (2018) 45:3–21 7
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The pharmacodynamic response R i.e., the number of








in which FðAbÞ is the drug-mechanism function through
which the drug in the biophase impacts the response,
kout;max the maximal elimination rate and Km the response
at which the elimination rate is half-maximal. The com-
bined biophase- and pharmacodynamic model is depicted
in Fig. 6. Prior to administration of the compound no
activity is observed, i.e., Rð0Þ ¼ 0.
Two observations inform the selection of the function
FðAbÞ:
(i) The data exhibit a zero baseline. This means that
Fð0Þ ¼ 0.
(ii) As the drug dose increases, the initial slope of the
data curves appears to reach a maximum.
They suggest a saturable drug-mechanism function which








in which Fmax (response units t1), FD50 (dose units) and
nH correspond to the maximum drug-induced efficacy, the
potency and the Hill-exponent.
The particular form of the turnover eq. (14) was selected
in light of the approximately linear elimination of response
which suggest saturation.
Mathematical analysis
In order to proceed from qualitative observations to
quantitative estimates about the model, we employ the
following observations:
• Decline of the response: After the time Tmax of
maximal response the graph has three conspicuous
properties: (i) it is straight, (ii) it does not change with
drug dose, and (iii) it exhibits a sharp angle as it
approaches the baseline.
These characteristics of the response curve offer us an
unusual insight into the dynamics of the model.
(a) At the time of maximal response Tmax the drug has
been eliminated and FðAbÞ  0, so that for t[ Tmax,











which shows that the slope of the graph is kout;max.
On the basis of the data we obtain the estimate:
kout;max  29 interruptions  minute1  h1 ð18Þ
(b) The sharp angle of the graph of R(t) as it approaches
the baseline, i.e., when R  0, can be accounted for
by a small value of Km.
(c) The response-time course associated with the higher
dose peaks at about Tmax ¼ 0:8 h. If one assumes that
approximately four half-lives have elapsed before
the drug has been cleared from the biophase, this
means that 4 	 t1=2  0:8 h, i.e., the half-life of the
drug in the biophase can be approximated by




 3:5 h1: ð20Þ
• Rise of the response For the higher dose the initial
segment of the graph of R(t) is approximately a straight
line. This suggest that during this period the stimulatory
function is saturated, so that FðAbÞ  Fmax, and,
Fig. 6 Schematic representation of the locomotor activity model
given by eqs. (13) and (14). Drug is supplied to the biophase,
eliminated through a first order process (k), and the amount of drug Ab
has a stimulating effect in the turnover equation for the response
through a nonlinear function FðAbÞ. Loss of response is modeled by a
saturable function with maximal (zeroth order) loss rate (kout;max), half
of which is reached when R ¼ Km
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¼ Fmax  kout;max ð21Þ
Since the data show an initial slope (dR / dt) of 168
interruptions/minute/h, we deduce that Fmax  168 þ
kout;max interruptions/minute/h. Using the estimate for
kout:max from the first observation, we conclude that
Fmax  168 þ 29 ¼ 197 interruptions  minute1  h1
ð22Þ
Remark It is evident from eq. (14) that at steady state, the
amount Ab;ss should be small enough so that the production
FðAb;ssÞ is smaller than the maximal rate of loss in order to
reach a steady state. Thus a basic assumption in this model
is that
FðAb;ssÞ\kout;max ð23Þ
• Time to maximal response Tmax. To obtain a ball park
value for the time to maximal response Tmax, we
approximate the function FðAbðtÞÞ, defined by (15), by
a step-function. This choice is based on the fact that, as
we argued before, the up-swing is more or less linear,
so that the function FðAbðtÞÞ appears saturated, and the
decline is also linear and in addition, dose-independent,
which suggests that FðAbðtÞÞ  0 after the peak-time
Tmax. Thus, if AbðtÞ is decreasing and crosses the level
FD50, say at time T, i.e., when AbðTÞ ¼ FD50, then we
postulate that the function FðAbðtÞÞ can be approxi-
mated by the step function
FðAbðtÞÞ ¼ Fmax  HeavðT  tÞ ð24Þ
Here HeavðsÞ denotes the Heaviside function which
equals ?1 if s
 0 and 0 if s\0. Thus, HeavðT  tÞ ¼ 1
if t T and HeavðT  tÞ ¼ 0 if t[ T .











Fmax if Ab [FD50

ð25Þ




1 þ xn ¼
0 if 0\x\1
1 if x[ 1

ð26Þ
The turnover eq. (14) can now be approximated by
dR
dt
¼ Fmax  HeavðT  tÞ  kout;max as long as R[ 0
ð27Þ
except for when R is small, specifically, when R ¼ OðKmÞ.
Starting at baseline, the solution RðtÞ of this equation is
given by:
RðtÞ ¼def
ðFmax  kout;maxÞ t if 0 t T
Fmax T  kout;max t if T\t\Tend

ð28Þ
where ð0; TendÞ is the maximal interval on which RðtÞ[ 0.
Since Fmax [ kout;max by eq. (23) it follows that R(t) is
increasing for 0\t\T . Plainly, R(t) is decreasing for





Because the biophase is assumed to follow intravenous
bolus dynamics, as described by eq. (13), it follows that
AbðTmaxÞ ¼ F  D  ek Tmax ¼ FD50 ð30Þ
We assumed that F ¼ 1, had taken the larger dose D ¼
5:62 lg kg-1, and estimated the elimination rate out of the
system to be k ¼ 3:5 h1. By visual inspection, the time of
maximal response was estimated by Tmax ¼ 0:8. Thus, we
conclude from eq. (30) that the potency can be estimated as
follows:
FD50 ¼ 0:34 lg  kg1: ð31Þ
Observe that for fixed Ab the steady-state response Rss is
formally given by




Recall that according to the assumption (23), we have
kout;max [FðAb;ssÞ.
Table 2 Model parameters for the locomotor activity example and
relative standard deviation (CV%)
Parameter Units Estimate Final est. CV%
k h1 3.5 5.96 4
Fmax Resp h
-1 197 249 4
FD50 lg kg
-1 0.34 1.02 4
nH – – 1.63 5
kout;max Resp h
-1 29 30.1 4
Km h1 Small 0.001 9
J Pharmacokinet Pharmacodyn (2018) 45:3–21 9
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Conclusion
Using mathematical methods we have been able to estimate
many of the parameters, such as k in the biophase model,
and Fmax and FD50, as well as kout;max and Km in the
pharmacodynamic model. These estimates can serve as
preliminary estimates for further refinement by statistical
software. By fitting the model (cf. equation (14)) to the
experimental response-time data in Fig. 5, the final
parameter estimates of Table 2 were obtained using the
nonlinear regression software WinNonlin 5.2 (Certara
Inc.).
The six model parameters generally had high precision
and were close to the analytically and graphically derived
initial parameter estimates. The mathematical reasoning in
the pattern recognition process thus proves to be useful
when unconventional data (as in this case) need to be
analysed.
Model predictions beyond the experimental range
Drug intake over long periods of time, such as is common
in the treatment of chronic diseases, may harbour risks
which are less evident over the period in which experi-
mental data is available. Simulations on the basis of
mathematical models, although predicated by the limited
availability of data, may then yield indications of what kind
of long time behaviour can be expected and how it can be
influenced.
Data, model and equations
We consider an example of such a situation discussed by
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Fig. 7 Individual plasma
concentration (ng/mL) versus
time profiles for six subjects
receiving a once-daily oral 1500
mg over a period of 3 weeks.
The cyan dots show the
observed plasma concentrations,
the black curve shows the
individual fit. The magenta
curves show the individual fits
of the 1-receptor model and the
grey curve shows the population
fit of the 2-receptor model
shown in Fig. 8
Fig. 8 The two-receptor model: the compound is supplied to the pool
compartment, from where it reaches the central, plasma, compartment
by a first order process (ka). From there it is bound by two receptors,
one located in red blood cells, with maximal capacity Bmax;1 and
dissociation constant Kd;1, and the other in a distributed ‘‘remote’’
compartment with maximal capacity Bmax;2 and dissociation constant
Kd;2, as well as eliminated by a first order process (ke) (cf. Snoeck
et al. [31])
10 J Pharmacokinet Pharmacodyn (2018) 45:3–21
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the plasma concentration of a compound was available for
a period of 480 hours. They are shown in Fig. 7.
This case-study involves a compound that is adminis-
tered into a pool compartment and absorbed in a central
compartment, from where it binds to two receptors through
Michaelis-Menten type reactions (cf. Michaelis and Men-
ten [30]) and dissociates according to first order kinetics.
The amounts (in mg) in pool- and central compartment are
denoted by, respectively, A1 and A2. Binding to one
receptor, which is probably located in the red blood cells is
fast (amount A3 mg) and binding to the other receptor,
which is located in what is called the ‘‘remote’’ compart-
ment, is slow (amount A4 mg). The distributional model is
illustrated in Fig. 8.
The model used to reach an optimal fit to the data shown
in Fig. 7 is based on a 2-receptor model due to Snoeck et al
[31] and is shown in Fig. 8. For comparison, the corre-
sponding 1-receptor model is obtained from the above
model by putting kRMT ¼ 0.
The 2-receptor model for the amounts of compound in
the four compartments (A1; . . .;A4) translates into the fol-
lowing set of differential equations:
dA1
dt
¼ D  q kaA1
dA2
dt








































where kRBC and kRMT are the distributional rate constants to
the receptors in the red blood cells and the remote recep-
tors, Bmax;1 and Bmax;2 the maximal capacity of these
receptors and Kd;1 and Kd;2 the associated dissociation
constants multiplied by the corresponding volumes. The
infusion rate is D  q mg/h, where q is the unit infusion rate,
i.e. q ¼ 1 mg/h and D is the amount of compound that is
supplied per hour.
It is assumed that initially, there is no compound in any
of the compartments or bound to the receptors, i.e.,
A1ð0Þ ¼ 0; A2ð0Þ ¼ 0; A3ð0Þ ¼ 0; A4ð0Þ ¼ 0:
ð34Þ
From t ¼ 0 onwards the compound is administered to the
pool compartment through a constant-rate infusion of D  q
mg/h, which in this study is taken to be 40 mg/h.
Two models are used to fit the data, which are given in
aqua. The black curves are the individual fits made with the
2-receptor model (33) and the magenta curves are the
individual fits made with the 1-receptor model obtained
from the system (33) by putting kRMT ¼ 0. The grey curves
are the population fits made with the 2-receptor model. In
Table 3 we give the parameter values obtained by fitting
the 2-receptor model to the data.
Consistent with these parameter values we assume
throughout this section that the receptors in the red blood
cells have a high affinity to the drug, a small capacity and a
short half-time, all relative to the remote receptor. Thus,
throughout we assume about the parameter values that:
Kd;1  Kd;2; Bmax;1  Bmax;2; kRBC  kRMT
ð35Þ
As drug flows into the system at a rate of D mg per hour,
the system eventually settles on a steady state:
(A1;ss; . . .;A4;ss). Plainly, the steady state amounts in the















Table 3 Parameter values
Parameter Value Unit Description
ka 2.48 h1 Absorption rate
ke 0.0111 h1 Ligand elimination rate
kRBC 1.06 h1 Rate constant to red blood cells (RBC)
kRMT 0.0000969 h1 Rate constant to remote receptors (RMT)
Bmax;1 77.7 mg Maximal capacity RBC
Bmax;2 259,000 mg Maximal capacity RMT
Kd;1 81.2 mg Dissociation constant 	 Vc
Kd;2 1680 mg Dissociation constant 	 Vc
q 1 mg/h Unit infusion rate
D 40 – Dose
J Pharmacokinet Pharmacodyn (2018) 45:3–21 11
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Note that A1;ss and A2;ss are independent of the binding
constants and the capacities of the receptors, and increase
linearly with the infusion rate D.
Remark As a preliminary observation we note that the
first equation in the system (33) can be solved explicitly,




ð1  eka tÞ
Thus, A1ðtÞ ! A1;ss as t ! 1 with a half-life of t1=2 ¼
lnð2Þ=ka ¼ 0:28 h, or 17 min. This is exceedingly short for
the time scale of interest. So effectively, it is permissible to
put A1ðtÞ  A1;ss. Therefore, we shall be mainly interested
in the amount of drug in the central or plasma compartment
and in the two types of receptors.
Simulations
In Fig. 9 we show how the amount of compound in the
plasma compartment, A2ðtÞ, evolves over time after the
infusion has been switched on. Evidently, two phases can
be distinguished: in the first phase, shown in the left panel,
A2 climbs to what appears to be a stationary state, which
we usually refer to as the Plateau value. Subsequently,
during a second phase, shown in the right panel, which
extends over a much longer time, A2 continues to climbs
towards its final steady state, albeit at a much slower pace.
In Fig. 10 we show simulations of the amount of com-
pound in the two receptors: A3 in the red blood cells and A4
in remote tissue. The left panel shows that A3 quickly
reaches a constant value, which is close to its final steady
state A3;ss (76.2 mg) computed from (36), the half-life
being about 5 h. The right panel shows how A4 evolves
over time and reaches its final steady state. Evidently, this
takes place on the same time scale as the second phase of
A2 shown in Fig. 9.
Summarising we distinguish three time scales in the
dynamics of the three-compartment model:
• The receptors in the red blood cells fill up fast.
Specifically, A3ðtÞ reaches its steady-state value with a
half-life of t1=2 ¼ Oð10Þ h,2 which is early compared to
the compound in the plasma compartment (A2) and in
the remote receptors (A4).
• The central compartment fills up in two phases: fairly
quickly up to an intermediate value, the Plateau Value
A2, with a half-life of t1=2 ¼ Oð102Þ h, and then much
more slowly, with a half-life of t1=2 ¼ Oð5 	 103Þ h, it
creeps up towards its final steady state A2;ss.
• The remote receptors fill up slowest: the amount of
drug A4ðtÞ reaches its steady-state level with a long
half-life t1=2 ¼ Oð104Þ h.
Mathematical analysis
In order to understand the observations made about the
simulations and answer such questions as (i) Which
receptor governs the dynamics in the initial phase? (ii)
How high does A2 rise in the first phase, i.e., what would be
a good estimate of the plateau value A2? (iii) What would
be the rate of convergence towards A2? and (iv) What is the
rate of convergence towards the final steady state in plasma
A2;ss, and analogous questions about the amount of drug in
the two types of receptors.
To answer these questions, we need to compare the
relative impact of the different terms in the system (33).
Because the amounts in the four compartments A1; . . .;A4
vary widely, as, do the rate constants given in Table 4, it is
necessary to transform to dimensionless variables and
normalise the amounts with well-chosen reference values.










































Fig. 9 Graphs show the amount versus time courses during a
constant-rate infusion over 103 and 105 h of compound in the second
compartment (A2ðtÞ (blue)), in the third (A3ðtÞ (red)) and the fourth
(A4ðtÞ (green)). The left panel shows how over a period of about 500
h A2 climbs to an intermediate steady state and the right panel shows
how A2 slowly climbs over a much longer period (5 	 104 h) to its
final steady state A2;ss. Details about the evolution of A3 and A4 are
shown in Fig. 10 (Color figure online)
2 T ¼ OðNÞ means that T is of the same order of magnitude as N.
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In light of the steady state values of A2, A3 and A4 shown in
(36), using D, Bmax;1 and Bmax;2 as reference values seems
appropriate. Thus, we introduce the variables
xðsÞ ¼ A2ðsÞ
D





; s ¼ kRBC t
ð37Þ
where we used 1=kRBC as a reference time.
Introducing these variables into the system (33) results
in the following system of differential equations:
dx
ds





































; l ¼ ke
kRBC









Note that for the parameter values of Table 4, we obtain
/ ¼ 0:94, l ¼ 0:010, e ¼ 0:0000914, j1 ¼ 2:03 and
j2 ¼ 42, and
Bmax;1
D
¼ 1:9425 and Bmax;2
D
e ¼ 0:59194 ð40Þ
By (34), the initial data are now xð0Þ ¼ 0, yð0Þ ¼ 0 and
zð0Þ ¼ 0.
Because e  1 the right-hand side of the third equation
of the system (38) is very small. This means that zðsÞ  0
for times s up to order 101 	 e1  103. Thus, up till such
time we may approximate the full system (38) by putting
z ¼ 0 and replace it by the simpler system which involves
only two equations and two unknowns: x and y:
dx
ds






















Note that while e is very small, when it is multiplied by
Bmax;2, as it is in eq. (41), the product is no longer small (cf.
eq. (40)).
This system (41) has a unique steady state ðx; yÞ, where
x can be computed as the root of the function f(x) defined
below:






and y can then be computed from the right-hand side of the
second equation in (41). Equation (42) is essentially a
second order equation in x which can be solved explicitly.
However, because of the many parameters the expression
for x is quite messy.
However, an important property of x can easily be
inferred by inspection: Note that (i) the function f(x) is
monotonically decreasing, (ii) f ð0Þ ¼ / and (iii) f ðxssÞ\0,
where xss ¼ A2;ss=D ¼ /=l. Therefore, 0\x\xss and
hence 0\A\A2;ss, in agreement with the simulations
shown in Fig. 9. Note that this conclusion is independent of
the values of the parameters. For the parameter values of
Table 4, the computed values for x and y are found to be
x ¼ 57:4 and y ¼ 0:965 ðA2 ¼ 2297 and A3 ¼ 75 mgÞ
ð43Þ
For small perturbations ðxþ nðsÞ; yþ gðsÞÞ, where nðsÞ and
gðsÞ are small compared to x and y, one can derive a linear
system of differential equations for nðsÞ and gðtÞ and com-
pute the rate with which orbits converge towards the steady
state ðn; gÞ ¼ ð0; 0Þ as s ! 1, and thus compute the ter-
minal slope or terminal elimination rate kz, defined by









































Fig. 10 Graphs of A2ðtÞ (blue), A3ðtÞ (red) and A4ðtÞ (green) versus
time. The left panel shows how over a period of about 50 h A3 climbs
to its steady state and in the right panel we see how A4 slowly climbs
over a much longer period (5 	 104 h) to its final steady state A4;ss
(Color figure online)






and the half-life by s1=2 ¼ lnð2Þ=kz in this phase. For the
parameter values of Table 4 this amounts to t1=2 ¼ k1RBC 
s1=2 ¼ 50 min (cf. [7]). Hence after 4 	 t1=2 ¼ 200 h the
plateau value has approximately been reached, consistent
with the simulations shown in Fig. 9.
Beyond the first phase, A2 and A3 are in quasi-equilib-




This enables one to reduce the system (38) to a different,
smaller, system making it possible to estimate the half-life
of the convergence towards the final steady state A2;ss. In
fact, it is found that the terminal slope of this phase is




¼ 7153 h ð45Þ
This is also consistent with the findings in Fig. 9 (Note that
t  s). For details of the derivation of these estimates we
refer to [7].
Conclusions
The mathematical analysis of the multiple receptor binding
system demonstrates that care should be taken when using
the model for making long-term predictions since such
predictions may involve extended periods which well
exceed the duration of experimental data. The final steady
state of both binding processes may then be significantly
higher than what is reached within the experimental time
span. Therefore, long term exposure data will be needed to
validate the model if used for future risk assessment.
The insights obtained from this mathematical analysis
will support the development of alternative models that
exhibit the same short to medium term kinetics, but dif-
ferent long term kinetics provided chronic exposure data
are available for model validation. For example, they could
quantify the impact of small leakage, which over extended
periods, may well be large (cf. [32]).
Vetting a model that yields counter-intuitive
concentration-versus-time graphs
In pharmacology, mechanistic mathematical models are
commonly developed on the basis of a combination of what
is known about the underlying physiology and statistical
methods which attempt to estimate the parameters in the
model using experimental data. The resulting model is then
employed to make predictions about optimal drug dose and
generally, about the temporal behaviour of the drug and its
effect. In general, before using the model in a clinical
environment, it is ‘‘challenged’’ against different drug
doses for which data sets exist, or for completely different
data sets. In some cases this yields unexpected results. To
get to the bottom of such an apparent anomaly a mathe-
matical study of the model is then advised. In this case
study we study a recent mechanistic model for Prolactin
(PRL) which yielded unexpected results about the
dynamics of prolactin (cf. [8] and [33]) when fitted to
pharmacokinetic data from Kozielska et al [34].
The prolactin model
This case study involves a model designed to investigate
the response of PRL to antipsychotic drugs, such as re-
moxipride or risperidone, in rats. The model, developed by
Movin-Osswald et al., [35], which is based on the classical
precursor-pool model [36–38] which distinguishes between
PRL in plasma, and PRL in lactotrophs that serves as a
precursor pool for the PRL in plasma. If P denotes the PRL
concentration in the lactotrophs and R the PRL concen-




¼ ks  krf1 þ SðCÞgP
dR
dt





Here ks denotes the zeroth order synthesis rate of PRL, kr
the first order rate of release of PRL from the lactotrophs
into plasma, and kel the first order elimination rate of PRL
from plasma. The drug, at concentration C(t) in the brain,
stimulates the release rate from lactotrophs through a






where Smax is the maximal extent of stimulation, SC50 the
drug dose for which stimulation reaches 50% of its maxi-
mal effect, and nH the Hill exponent.








Stevens et. al., [33] incorporated the fact that release of
prolactin by the lactotrophs into plasma has a stimulating
effect on the production of prolactin resulting in a positive
feedback loop (see Fig. 11). See also Friberg et. al., [39].
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They incorporated that effect into the model (46)
through a multiplicative function of the synthesis rate ks
that depends on the prolactin concentration in plasma,




¼ ksf1 þ f ðRÞg  krf1 þ SðCÞgP
dR
dt





In this model f(R) is a non-decreasing function of R
endowed with the following properties: (i) For R
R0, the
function f(R) is strictly increasing which vanishes when
prolactin is at baseline, i.e., when R ¼ R0. (ii) To guard
against sudden collapse, the feedback is switched off when
the PRL concentration drops below the baseline value, i.e.,
f ðRÞ ¼ 0 when R\R0. Stevens et al [33] chose a function
of the following form:
f ðRÞ ¼ f0ðRÞ  HðR R0Þ; f0ðRÞ ¼
EmaxðR R0Þ
EC50 þ ðR R0Þ
ð50Þ
in which Emax denotes the maximal stimulatory effect on
the synthesis rate ks and EC50 the increase of the PRL
concentration above the baseline value at which half the
maximal effect is achieved. In addition, HðR R0Þ is the
Heaviside function which vanishes for RR0 and so
ensures that f ðRÞ ¼ 0 for R\R0, and equals to 1 for R
R0
so that f ðRÞ ¼ f0ðRÞ for R
R0.
Counterintuitive behaviour
When Proost and Taneja (Private communication) used PK
data for risperidone obtained by Kozielska et al [34] (cf.
Appendix) to drive the model above, they found the fol-
lowing counterintuitive behaviour (cf. Fig. 12):
1) For drug doses D ¼ 0:1 and 1.0 mg/kg they observed
that simulations return R to the baseline R0 as
t ! 1.
2) For drug doses D ¼ 0:05 and 2.0 mg/kg they
observed that simulations do not return R to the
baseline R0 as t ! 1, but converge towards a higher
constant level, which we denote by R1.
Fig. 11 Lactotrophs-Prolactin
pool model with positive
feedback f(R)
Fig. 12 Counterintuitive dynamics seen in PRL concentration in
plasma (on the left): for D ¼ 0:1 and 1 mg/kg the PRL-concentration
returns to baseline, whilst for D ¼ 0:05 and 0.2 mg/kg it converges to
a higher constant state. The right figure shows graphs of the drug
concentration versus time corresponding to the four doses based on
the model by Kozielska et al [34]
J Pharmacokinet Pharmacodyn (2018) 45:3–21 15
123
3) The PK is fast, in that the half-life of drug in the
central compartment is around 1 h, whilst the time
for R to reach R0 is about 10 h and to reach R1 is
around 40 h.
This suggests that, (i) when CðtÞ  0, there exists besides
the baseline R0 an additional steady state R1 [R0, and (ii)
the drug dependence of the dynamics is not monotone and
quite sensitive to drug dose. For practical situations this is
very critical so that it is important to find the reasons for
this behaviour.
In order to understand these phenomena it is necessary
to study the mathematical properties of the model (49) with
positive feedback function (50) more closely. That will be
done in the next subsection.
Mathematical analysis
To simplify the equations and reduce the number of
parameters, we introduce dimensionless variables. To this
end we scale P and R by their respective baseline values
and time by 1=kel and put:
x ¼ P
P0
; y ¼ R
R0
; s ¼ kel t ð51Þ
Introducing these variables into the system (49) and the
feedback function f(R) we obtain
dx
ds
¼ a 1 þ uðyÞ  wðsÞ xf g
dy
ds







where wðsÞ ¼ 1 þ SðCðtÞÞ and
uðyÞ ¼ bðy 1Þ





Suppose that the drug concentration is constant, i.e.
CðtÞ  C
 0, and wðsÞ  w ¼ SðCÞ. Then, by (52) a sta-
tionary solution ðx; yÞ satisfies the pair of equations
1 þ uðyÞ ¼ w  x and w  x ¼ y
Substituting the second equation into the first yields the
following equation for y:
1 þ bðy 1Þ
cþ ðy 1Þ ¼ y ð54Þ
This is a quadratic equation in y which has the roots:
y0 ¼ 1 and y1 ¼ 1 þ b c ð55Þ
Plainly, y0 corresponds to R0, the baseline in the absence of
positive feedback. However y1 corresponds to a new sta-
tionary solution which is introduced by the positive feed-
back, denoted by R1.
It is illustrative to follow the dynamics of the system in
what one may refer to as the state space, the (x, y)-plane in
which the state, defined by x and y, travels. It is often called
the Phase plane and the trajectory, traced by the concen-
tration pair (x(t), y(t)), is called the Orbit. Plainly, at each
point (x, y) in this plane the velocity vector q ¼
ðdx=ds; dy=dsÞ can be computed from the system (52).
States at which x increases with time ðdx=ds[ 0Þ and
where x decreases with time ðdx=ds\0Þ are separated by
curves Cx where dx=ds ¼ 0. Similarly, Cy separates states
where y increases, respectively decreases. The curves Cx
and Cy are called the Null clines. Clearly, the stationary
states are located at the points where Cx and Cy intersect.
When C ¼ 0, then by the system (52), the null clines are
given by
Fig. 13 Null clines in the phase plane spanned by the dimensionless concentrations of PRL in lactographs (x) and in plasma (y) for three ranges
of b with respect to c (Here c ¼ 1 and b ¼ 0:2; 1; 3). The arrows indicate the direction of the velocity field q: vertical on Cx and horizontalon Cy
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Cx : y ¼ x and Cy : y ¼ 1 þ
cðx 1Þ
b ðx 1Þ ;
ðx 6¼ bþ 1Þ
ð56Þ
These null clines are shown in Fig. 13 for c ¼ 1 and b ¼
0:2; 1:0 and 3. Notice that Cy is fixed and Cx moves to the
right and up as b increases. As predicted by eq. (55), we
see that the corresponding steady states are, besides
ðx0; y0Þ ¼ ð1; 1Þ: ðx1; y1Þ ¼ ð0:2; 0:2Þ when b ¼ 0:2, and
ðx1; y1Þ ¼ ð3; 3Þ when b ¼ 3.
The null clines are very helpful in determining various
aspects of the dynamics of the system, such as (i) the sta-
bility of the steady states, (ii) the large-time behaviour of
orbits: e.g. where they go to and how they approach the
stable steady states and (iii) identification of invariant
regions, i.e., regions in the plane which trap orbits. Thus,
the arrows in Fig. 13 suggest that when the positive feed-
back is small, i.e., when b ¼ Emax is small, then ðx0; y0Þ ¼
ð1; 1Þ is stable because all the arrows point towards it.
However, when the positive feedback becomes stronger,
and specifically, when b becomes larger than c, then
ðx0; y0Þ loses its stability and arrows point to ðx1; y1Þ.
When the parameters in the system explicitly depend on
time, the situation is more complex. In the system (52) the
parameters are all constants except the coefficient wðsÞ
which depends on s. However, since CðtÞ ! 0 very
quickly (cf. Fig. 12, right panel), for most of the orbit we
may put C ¼ 0, and hence w ¼ 1, after a brief initial
period.
The specific parameter values employed for the system
(52) by Stevens et al [33] are given in Table 4.
They yield for the dimensionless constants: a ¼ 0:10,
b ¼ 3:47 and c ¼ 1:99. Thus, for the data used in [33] we
conclude that b[ c, so that the right-hand graph in Fig. 13
applies. For the baseline we obtain R0 ¼ 6:24 ng mL-1
and, using eq. (55), we obtain for the upper steady state
R1 ¼ R0 	 y1 ¼ R0ð1 þ b cÞ ¼ 15:48 ng mL-1, in
agreement with the simulation shown in Fig. 12.
Summarising and rephrasing the observations made in
the simulations shown in Fig. 12 we can state that
RðtÞ ! R0 as t ! 1 when D ¼ 0:1&1:0 mg=kg;
RðtÞ ! R1 as t ! 1 when D ¼ 0:05&2:0 mg=kg

ð57Þ
and the question is, why the PRL concentration does not go
back to the baseline R0 for any initial dose. In the next
subsection we attempt to shed light on this observation.
Behaviour explained
In order to understand why the behaviour of the PRL-
concentration is so sensitive to the drug dose, we turn to the
phase plane and follow the orbit traced by the concentra-
tion pair (x, y) from its starting point ðx; yÞ ¼ ð1; 1Þ all the
way towards its limiting state ðx1; y1Þ. Specifically, we
wish to know when the orbit tends to ðx0; y0Þ and when to
ðx1; y1Þ, and how the drug dose D enters into this selection.
For simplicity we first study the dynamics of the system
(52) in the absence of a cut-off of the positive feedback.
For this case we show in Fig. 14 the orbits in the phase
plane for the drug doses D ¼ 0:05, 0.1, 1.0 and 2.0 mg/kg.
We observe in Fig. 14 that after a rapid introduction of
risperidone, all orbits leave the baseline ðx0; y0Þ ¼ ð1; 1Þ
move up and to the left along an orbit which is initially
tangent to the line
‘ : y ¼ 1 þ 1
a
ð1  xÞ ¼ 1 þ 10 	 ð1  xÞ: ð58Þ
After describing a big loop the orbits all return to a
neighbourhood of the baseline ðx0; y0Þ ¼ ð1; 1Þ from where
they started. However, because b[ c the baseline is
unstable and orbits move away from it, with the exception
of two orbits: one from above and one from below, which
tend towards ðx0; y0Þ. Orbits which pass above these
‘‘stable orbits’’ (cf. D ¼ 0:05 and 2 mg/kg) ultimately
converge towards the second equilibrium solution ðx1; y1Þ.
Those which pass below (cf. D ¼ 0:1 and 1 mg/kg) leave
the first quadrant and they do this through the y-axis, below
the line y ¼ 1. This dichotomy is clearly demonstrated in
Fig. 14.
Table 4 Parameter values used
in [33]
Parameter Value Unit Description
ks 35.7 ng mL
-1 h-1 Synthesis rate PRL
kr 0.59 h1 Release rate PRL
kel 5.7 h1 Elimination rate PRL
Smax 25 – Maximal stimulation
SC50 0.08 ng mL
-1 h Drug concentration when stimulation is half-maximal
Emax 3.47 – Maximal positive feedback
EC50 12.4 ng mL
-1 h Value of R R0 when feedback is half-maximal
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Evidently, orbits entering the neighbourhood of ðx0; y0Þ
are very sensitive to small changes in paramater values or
to the drug dose: a small change may flip them to the other
side of the two stable orbits and change their subsequent
course dramatically. This is the phenomenon that Proost
and Taneja observed.
Including cut-off
Of course, by definition, both x and y cannot be negative
and therefore realistic orbits should lie in the first quadrant.
In order to ensure that x[ 0 and y[ 0, Stevens et al. cut
off the positive feedback as soon as R\R0 or y\1. This
affects the null cline Cx below the line y ¼ 1, i.e. in the
region fðx; yÞ : y\1g, as shown in Figure 15. The cut-off
makes Cx vertical below y ¼ 1. Since the velocity vector
on Cx is also vertical, this section of Cx is invariant and
orbits cannot cross it.
Thus, the orbits are unaffected as long as they stay
above the line y ¼ 1. However, when they dip below this
line they change direction, move to the right and generally
are captured in the triangular region between the two null
clines Cx and Cy and the x-axis. In this region q points up
and to the right and orbits can readily be shown to con-
verge to the baseline ðx0; y0Þ ¼ ð1; 1Þ as time tends to
infinity. Thus
xðsÞ % 1 and yðsÞ % 1 as s ! 1 ð59Þ
This is what we see demonstrated in the simulations of
Fig. 16.
As we have shown, thanks to the cut-off of the positive
feedback, we now observe two types of large time
behaviour:
(i) Orbits converging to the baseline ðx0; y0Þ and
(ii) Orbits converging towards the steady state created
by the positive feedback. In both cases, orbits
approach their limits from below and from the left.
The fact that orbits pass through a neighbourhood
of (1,1) makes for very sensitive dependence on the
drug dose.
Fig. 15 Null clines in the phase
plane spanned by the
dimensionless concentrations of
PRL in lactographs (x) and in
plasma (y) for c ¼ 1 and b ¼ 3
with Cut-off (Left) and without
Cut-off (Right). The arrows
indicate the direction of the
velocity field q: vertical on Cx
and horizontal on Cy. Note that
below the line y ¼ 1 the
direction of the velocity vector
q has changed: With cut-off it
points to the right and without
cut-off it points to the left

































Orbits in the phase plane y versus time τ .
Fig. 14 Simulations of the
positive feedback model without
cut-off in the phase plane
spanned by the dimensionless
concentrations of PRL in
lactographs (x) and in plasma
(y) (Left) and dimensionless
PRL in plasma versus
dimensionless time (s) (Right)
The doses D of risperidone are:
D = 0.05, 0.1, 1.0 and 2.0 mg/
kg. The drug PK is simulated
using the PK model for iv dose
of risperidone [34] (cf.
Appendix A )
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Conclusion
The mathematical analysis of the prolactin model with
positive feedback has explained the unexpected behaviour
of orbits and in particular their sensitivity to the drug dose.
However, in the process it has done much more and given
us great insight in the properties of the model. Thus, it has
revealed the existence of two constant steady states, even
in the absence of any drug-driven stimulation, i.e., two
baselines of which one corresponds to the old baseline
ðP0;R0Þ. Only if b\c, i.e., if Emax\ðEC50  R0Þ, is the old
baseline stable.
Overall conclusions
We have highlighted the impact of mathematical pharma-
cology in four case studies derived from previously pub-
lished data and analyses ([5–7] and [8]). In case study 1, we
derive relations between quantities involved in TMDD
systems at steady-state, such as target versus ligand and
ligand-target complex versus ligand. These relationships
give rise to a new expression of Potency, L50. This potency
parameter is a conglomerate of binding affinity (kon & koff),
target turnover (kdeg), and ligand-target complex removal
(keðRLÞ). Its applications will range from descriptions of
in vitro and in vivo correlations to assessment of deter-
minants of pharmacologically efficacious concentrations.
The second case study involves locomotor activity and
demonstrates how mathematical analysis, when combined
with pattern recognition, can serve as a refined instrument
for extracting qualitative as well as quantitive properties
out of data sets, such as model structure, rate constants and
dose dependence. Thus, Visual Inspection yields valuable
parameter estimates which can be used in statistical data
analysis for further refinement.
The third case study serves as a warning against the
dangers of using multiple rate binding models for extrap-
olating beyond the experimental time range. This study
emphasises the need for long-term data for making small,
but in the long term significant corrections to exposure or
environmental conditions.
Deeper mathematical study may be required to uncover
mysteries in the dynamics of PK-PD systems, such as large
computational times or unexpected behaviour. The fourth
case study focusses on the latter: a semi-mechanistic pool-
precursor model for the dynamics of prolactin is found to
exhibit—what appears to be—random dependence on drug
dose. Small changes of the dose are seen to cause step
changes in terminal behaviour. Thus, mathematical analy-
sis exposes and makes explicit weaknesses of the model.
The take-home messages from this Communication are
that mathematical and analytical techniques serve their
purpose when we need to chisel out new structures (Case
study #1), quantify patterns (Case study #2), make what-if?
predictions (Case study #3) and diagnose models with
hidden pathologies (Case study #4).
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Orbits in the phase plane y versus time τ .
Fig. 16 Simulations of the positive feedback model with cut-off in the
phase plane spanned by the dimensionless concentrations of PRL in
lactographs (x) and in plasma (y) (Left) and dimensionless PRL in
plasma versus dimensionless time (s) (Right) for the same doses D of
risperidone as in Fig. 13: D = 0.05, 0.1, 1 and 2 mg/kg. The drug PK is
simulated using the PK model for iv dose of risperidone [34] (cf.
Appendix A)
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Appendix
PK used by Kozielska et al [34]
Kozielsky et al used a simple two-compartment model
involving a central and a peripheral compartment in which
the drug-amounts were denoted by, respectively, Ac and Ap.
The drug entered the central compartment from a depot


































where ka denotes the first-order rate with which drug is
transported from the depot into the plasma compartment
CL the clearance from the plasma compartment and CLd
the distributional clearance between the plasma- and the
peripheral compartment. The volumes of the plasma- and
the peripheral compartment are denoted by Vc and Vp,
respectively. The PK parameter values used by Kozielska
et al are given in Table 5.
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